Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock?

Novo Nordisk A/S ADR (NVO), a trailblazer in the weight-loss revolution, has endured a bruising 2025. The Danish pharma giant has been hit by trimmed growth forecasts, pricing pressure, rising competition from Eli Lilly (LLY), mass layoffs, dramatic leadership changes, and even a high-profile public bidding war with U.S. rival Pfizer (PFE). Although Novo’s blockbuster Ozempic enjoyed a four-year head start over Lilly’s Mounjaro, Lilly has now pulled ahead in U.S. prescriptions.

Novo’s struggles to keep up with demand also allowed compounding pharmacies to step in, chipping away at its market share and making 2025 one...

Fundamentals

See More
  • Market Capitalization, $K 233,966,000
  • Shares Outstanding, K 4,465,000
  • Annual Sales, $ 42,108 M
  • Annual Income, $ 14,643 M
  • EBIT $ 19,514 M
  • EBITDA $ 22,285 M
  • 60-Month Beta 0.67
  • Price/Sales 5.57
  • Price/Cash Flow 13.23
  • Price/Book 8.66

Options Overview Details

View History
  • Implied Volatility 37.45% (-0.21%)
  • Historical Volatility 42.75%
  • IV Percentile 7%
  • IV Rank 22.04%
  • IV High 70.99% on 04/08/25
  • IV Low 27.96% on 12/31/24
  • Expected Move (DTE 6) 1.42 (2.71%)
  • Put/Call Vol Ratio 0.29
  • Today's Volume 96,345
  • Volume Avg (30-Day) 90,989
  • Put/Call OI Ratio 0.72
  • Today's Open Interest 1,526,521
  • Open Int (30-Day) 1,664,662
  • Expected Range 50.98 to 53.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.90
  • Number of Estimates 3
  • High Estimate 0.91
  • Low Estimate 0.89
  • Prior Year 0.91
  • Growth Rate Est. (year over year) -1.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.08 +13.72%
on 12/09/25
53.63 -2.29%
on 12/24/25
+3.69 (+7.58%)
since 11/26/25
3-Month
43.08 +21.63%
on 11/24/25
60.90 -13.96%
on 10/06/25
-3.21 (-5.77%)
since 09/26/25
52-Week
43.08 +21.63%
on 11/24/25
93.80 -44.14%
on 02/25/25
-35.25 (-40.22%)
since 12/26/24

Most Recent Stories

More News
As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock?

As Novo Nordisk’s FDA-approved Wegovy pill sets up a high-stakes comeback, should NVO be back on investors’ radar now?

NVO : 52.40 (-0.30%)
$SPX : 6,929.94 (-0.03%)
LLY : 1,077.75 (+0.07%)
PFE : 25.09 (+0.24%)
Pfizer Adds to Its Big Bet on Weight Loss Drugs

A month after acquiring obesity biotech Metsera, Pfizer's expanding in the weight loss drug market after signing a licensing agreement for a weight loss pill.

NVO : 52.40 (-0.30%)
JNJ : 207.63 (-0.07%)
LLY : 1,077.75 (+0.07%)
REGN : 784.97 (+0.16%)
PFE : 25.09 (+0.24%)
Golden Cross Alert: 3 Stocks With Major Upside Potential

Three stocks flashing a golden cross—Sun Communities, Darling Ingredients, and Wave Life Sciences—may offer strong upside potential heading into 2026

DAR : 35.97 (+1.47%)
SUI : 124.26 (-0.15%)
NVO : 52.40 (-0.30%)
WVE : 17.77 (-2.63%)
LLY : 1,077.75 (+0.07%)
5 High Short-Interest Stocks to Buy Before Q1 2026

High short interest in critical tech names points to a robust rebound for these stocks and others in 2026. The Q4 reporting cycle is a likely catalyst.

NVDA : 190.53 (+1.02%)
SOUN : 10.70 (-1.83%)
MP : 53.38 (-2.13%)
JPM : 327.91 (-0.38%)
HIMS : 34.31 (-1.04%)
NVO : 52.40 (-0.30%)
SMCI : 30.64 (+0.29%)
APLD : 24.05 (-6.49%)
As Eli Lilly Cuts Zepbound Prices, Should You Buy, Sell, or Hold LLY Stock?

Eli Lilly has decided to slash prices of its weight loss drug Zepbound, making it more accessible to customers.

$SPX : 6,929.94 (-0.03%)
NVO : 52.40 (-0.30%)
LLY : 1,077.75 (+0.07%)
Should You Buy the Massive Dip in Novo Nordisk Stock?

Novo’s failed Alzheimer’s bet sparked a sharp selloff, leaving investors debating whether this bruising dip is a bargain or not.

NVO : 52.40 (-0.30%)
LLY : 1,077.75 (+0.07%)
Hims, Block, and NRG Just Launched Huge Stock Buybacks

Buyback capacity just got a big-time boost at Hims, Block, and NRG Energy. The three firms authorized more than $8 billion in buybacks combined.

NRG : 160.88 (+0.20%)
HIMS : 34.31 (-1.04%)
NVO : 52.40 (-0.30%)
XYZ : 66.27 (+0.33%)
The Hidden Engine Behind Billion-Dollar Pharma Deals - And Why Nasus Pharma May Be Building One of Its Own

WSW, NY, 24th November 2025, FinanceWire … Read More

NVO : 52.40 (-0.30%)
LLY : 1,077.75 (+0.07%)
NSRX : 7.61 (+1.40%)
The Saturday Spread: Using Data Science to Pick Out the Most Compelling Discounts (NVO, SOFI, FAST)

By leveraging the power of bespoke algorithms, advanced traders can go beyond cookie-cutter finpub content to discover true opportunities.

NVO : 52.40 (-0.30%)
SOFI : 27.07 (-1.49%)
FAST : 41.56 (-0.65%)
Eli Lilly Stock Joins the $1 Trillion Club as LLY Hits New All-Time Highs

Eli Lilly (LLY) just became the first healthcare company to join the $1 trillion market cap club. Shares are trading at a new all-time high on Friday, Nov. 21. The stock is up 40% in the past year and...

NVO : 52.40 (-0.30%)
LLY : 1,077.75 (+0.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 54.38
2nd Resistance Point 53.70
1st Resistance Point 53.05
Last Price 52.40
1st Support Level 51.73
2nd Support Level 51.05
3rd Support Level 50.40

See More

52-Week High 93.80
Fibonacci 61.8% 74.42
Fibonacci 50% 68.44
Fibonacci 38.2% 62.46
Last Price 52.40
52-Week Low 43.08

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar